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Amyotrophic Lateral Sclerosis (ALS), the most common of the Motor Neuron 
Diseases (MND), is characterized by the progressive degeneration of the upper and lower 
motor neurons. Death ensues in 3-5 years from diagnosis, which consists of scoring and a 
physical examination to rule out other motor disorders. Riluzole is the only drug approved so 
far and it offers only a modest 2-3 months of extension of life with little symptomatic relief. 
The search for an effective therapy is a daunting uphill task with numerous agents failing in 
clinical trials despite showing efficacy in the preclinical disease endpoints. Using Gas 
Chromatography/Time-Of-Flight Mass Spectrometry (GC/TOFMS) as the analytical platform, 
we conducted an untargeted metabonomic profile study, to identify potential metabolites in 
the blood samples of SOD1G93A mouse model of ALS that can potentially serve as 
biomarkers to aid preclinical development of interventions. In all, 479 putative metabolite 
peaks were detected in the blood samples by the GC/TOFMS. After subjecting the data to 
PLS-DA, by applying a criterion of VIP value of more than 1.2, 95 metabolite peaks were 
selected as marker metabolites that separate SOD1G93A Tg mice and their matched 
controls. By applying further selection criteria of CV% < 30% and p < 0.05 using Welch’s T-
test, we present a panel of metabolites that cover some of the hallmark pathways of the 
disease, ranging from energy metabolism to mitochondria health. Sharing common 
pathways and specific metabolites with a clinical metabonomic study, our study offers 
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1.1  Amyotrophic Lateral Sclerosis 
 
Amyotrophic Lateral Sclerosis (ALS), the most common of the Motor Neuron Diseases 
(MND) [1], is characterized by the progressive degeneration of the upper and lower motor 
neurons. Upper motor neurons include neurons that are located in the motor region of the 
cerebral cortex or the brain stem that carry movement information through a common 
pathway to the lower motor neurons in the brain stem and spinal cord that connect directly 
to muscles. As the disease progresses, at some point, the motor neurons can no longer send 
signals to the muscles leading to muscle weakening and eventual atrophy resulting in 
paralysis. ALS begins in the limbs, usually the arms, in about two-thirds of patients. The first 
symptoms are most often unilateral and focal. Early findings include foot drop, difficulty 
walking, and loss of hand dexterity or weakness when lifting the arms. As limb function 
deteriorates, patients become dependent on caregivers. Death of the patient ensues in 3-5 
year after diagnosis usually due to the ultimate failure of the patient’s respiratory system 
[2]. Incidence rates for ALS range from 1.2 - 4.0 in 100,000 person per year in Caucasians [3-
6]. The incidence rates increase with age, peaking between 70 and 80 years, and are higher 
in men than women [7].  
ALS is diagnosed based on the medical, as well as the family history of the patient, and 
the physical examination of the patient. It can be difficult to diagnose ALS because 
symptoms can vary among individuals. The disease is clinically heterogeneous even among 
family members harboring the same gene mutation; a single etiology can lead to numerous 
clinical syndromes. A combination of electromyography (EMG) and nerve conduction tests is 
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used for diagnosis.  
ALS is classified into familial ALS (FALS) and sporadic ALS (SALS), with FALS making up 
approximately 10% of all ALS cases. It has been almost 150 years since Jean-Martin Charcot 
first described the disease in the 1860s [8]. While ALS is nearly as mysterious today as it was 
in the first part of the 20th century, recent breakthroughs in understanding FALS have led to 
new hypotheses for disease triggers and mechanisms of propagation [9, 10]. Known 
mutations now account for much of the rare instances of inherited ALS with mutations in the 
human superoxide dismutase 1 (SOD1) gene making up a large part of the FALS cases [11], 
other causative genes including C9ORF72 [12], TDP43, FUS and OPTN, have recently been 
suggested to be involved as well [9, 10]. SALS is also thought to have both genetic and 





1.2  ALS Drug Discovery, Disease Model and Clinical Study 
 
Riluzole was approved by the FDA in 1996 for the treatment of ALS and remains the only 
therapy available today. Riluzole possesses anti-glutamatergic properties that reduces 
excitotoxicity in ALS, providing a modest 2-3 months of life extension, however without 
symptomatic relief [13]. Moreover, riluzole yields side effects like diarrhea, dizziness, 
fatigue, nausea, and somnolence. 17 years and numerous clinical trials later, there is still no 
emergence of a disease-modifying treatment for ALS [14]. The lethal prognosis and the 
absence of effective treatments for ALS meant that all care given to patients is palliative 
[15]. 
In 1994, Gurney and colleagues created the SOD1G93A transgenic mouse line, which 
carries a mutant human SOD1 cDNA inserted into the mouse genome [16]. These mice carry 
a causative mutation (a glycine-to-alanine change at residue 93) in an array of ~25 copies of 
the human transgene, with the mutant human protein causing a toxic gain of function and 
recapitulate many features of ALS, including axonal and mitochondrial dysfunction, 
progressive neuromuscular dysfunction, gliosis and motor neuron loss [16, 17]. The model 
has an onset of paralysis at ~90 days, accompanied by degenerative changes to motor 
neurons that compare well with human ALS pathology [18], and death by ~135 days, 
depending on strain background as well as the actual mutation on the human SOD1 gene. 
The SOD1G93A mouse has been widely used for research ranging from basic molecular cell 
biology through to extensive drug trials. Only until recently, the mutant human SOD1G93A 
transgenic mouse model (the SOD1 mouse) had been the only available model of ALS to 
evaluate and progress candidate compounds into clinical trials. 
The SOD1 mouse has been used extensively to study compounds or approaches with 
possible therapeutic value [19]. However the validity of this model has been questioned 
4
 
because many compounds demonstrating efficacy in the mouse model were ineffective in 
human studies [20]. The fundamental differences between the genetic mouse model and 
the genetically and clinically heterogeneous human ALS population had been heavily 
debated [21]. In addition, the ‘positive’ results observed in the mouse model are often 
derived from inadequately powered studies in which administration of the compound began 
before disease onset. On the contrary, human clinical trials were typically performed in 
patients who had already passed the stage of disease onset.  
Despite these differences, many studies have documented that there is a wide range of 
cytotoxic events common to the ALS mouse model and the human SALS patient, including 
evidences of excitotoxicity and oxidative injury, markers and genes reflecting programmed 
cell death, and neuroinflammation [22]. Recently 4 genetic biomarkers found in human bone 
marrow mesenchymal stem cells (hMSC) obtained from SALS patients are also found to be 
differentially and spatiotemporally expressed in the brain, spinal cord and muscle of the 
SOD1G93A mouse model [23]. The differential expressions were observed both at the pre-
symptomatic and symptomatic stages of the disease. These results support the possibility of 
a molecular link between SALS and FALS and suggest common pathogenetic mechanisms 
involved in both types of ALS. As riluzole is effective in both the SOD1 mouse [24] and large 
populations of SALS patients, the well-established SOD1 mouse may continue to be 
applicable in our search for potential therapies for ALS before the industry is confident in 
adopting the newer ALS mouse models [25]. Importantly, the design of preclinical/clinical 
trials needs to be reconsidered so as to develop innovative methods in investigating ALS 
therapies. One example is the development of biomarkers that characterise the 
heterogeneity of ALS where they can be subsequently explored to improve the early 
diagnosis and the efficient clinical trials of ALS [19, 26].  
As with many CNS disorders, ALS is likely to arise from the dynamic dysregulation of 
several gene and protein regulatory networks, and downstream metabolic pathways, 
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reflecting complex endogenous and exogenous perturbations of the systems biology. An 
overview of biochemical abnormalities associated with CNS disorders has been described 
[32], and findings are derived from studies often limited to quantifying a single, or a few 
metabolites. Therefore, the application of global metabonomic approaches could provide 
unprecedented insights into mechanistic understanding of ALS [33]. In addition, 
metabonomic analyses may provide opportunities to identify novel biomarkers for diagnosis 






1.3  Metabonomics in the study of ALS 
 
In contrast to classical biochemical approaches that often focus on a single biomarker, 
metabonomics, an emerging field of –omics, involves the collection of quantitative data on a 
broad series of metabolites in an attempt to gain an overall understanding of metabolism 
and/or metabolic dynamics associated with conditions of interest, including state of disease 
and drug exposure [27]. Metabonomics measures the dynamic multiparametric response of 
a living system’s metabolome to genetic modifications or pathophysiological stimuli [28, 29]. 
Several terms have been used to describe the study of the metabolome, which include 
metabolomics, metabonomics, metabolic profiling, metabolic footprinting and metabolic 
fingerprinting. As mentioned in the previous section, metabonomics allows one to survey 
global changes in metabolic pathways and gain a holistic understanding of the changes in a 
biological system [30, 31], since fluctuations in the metabolome is a result of a complex 
interactions among the genome, transcriptome, proteome, and the environment [27, 30].  
Using high-resolution proton-magnetic resonance spectroscopy (1H-MRS) as the 
analytical platform, age-dependent alterations in the cerebral and spinal metabolic profiles 
of the SOD1G93A mouse model were determined [34]. In the spinal cord of the mouse, 
significantly decreased levels of N-acetyl aspartate (NAA) were already detected 60 days 
before the average disease onset. In addition, glutamine and c-aminobutyric acid 
concentration levels were significantly diminished at the pre-symptomatic stage of 75 days 
postpartum. These metabolic changes were further progressive in the course of the disease 
and started to involve the brainstem on day 75. 1H-MRS studies of ALS in humans were 
performed several years before this mentioned study, demonstrating that either the 
concentration of NAA [35] or ratios NAA ⁄ creatine [36] and NAA ⁄ choline [37] are reduced 
in the motor cortex, that is in turn interpreted as evidence of neuronal loss due to ALS or 
MND. However, the claim of NAA being a potential biomarker for ALS/MND needs to be 
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taken with caution; NAA has also been said to be involved in Alzheimer’s Disease (AD) [38], 
depression [39], Systemic Lupus Erythematosus (SLE) [40], Multiple Sclerosis (MS) [41] and 
even in head trauma [42].  
Metabonomic research in ALS has largely employed Nuclear Magnetic Resonance / 
Magnetic Resonance Imaging / Magnetic Resonance Spectroscopy (NMR/MRI/MRS) as the 
analytical platform [34, 43, 44]. Being a non-invasive technique, NMR/MRI/MRS has a 
unique advantage considering the potential of translation of the analytical protocol to 
human patients. However, one limitation of magnetic resonance is its inability to detect a 
large number of metabolites due to its limited coverage of chemical space [45]. As such, 
there is an obvious need to detect a larger number of metabolites, so as to achieve a 
comprehensive understanding of the metabolic perturbation associated with the complex 
disease. Gas chromatography / time-of-flight mass spectrometry (GC/TOFMS) has been 
proven to be a potentially useful metabolic profiling platform based on its high sensitivity, 
peak resolution and reproducibility [46]. In addition, availability of an electron impact (EI) 
spectral library further facilitates the identification of diagnostic biomarkers and aids the 
subsequent mechanistic elucidation of pathological phenotypes [47]. The application of 
GC/TOFMS to study ALS has been investigated previously [48, 49]. In the first study, SALS 
patients were found to possess heterogeneous metabolite signatures in the cerebrospinal 
fluid (CSF), where the profiles of some patients were almost identical to controls [48]. 
However, the CSF metabolic profile of FALS patients without SOD1 mutation is less 
heterogeneous than that of the SALS patients [48]. The metabolome of the CSF of 17 FALS 
patients with a SOD1 gene mutation was found to form a separate homogeneous group [48]. 
A separate study done by this same group further showed that FALS patients carrying a 
mutation in SOD1 have characteristic patterns in the CSF metabolome that are statistically 
different from all ALS patients (both SALS and FALS) not carrying a SOD1 mutation [49]. In 
addition, subjects carrying the specific D90A mutation in SOD1 showed significant 
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differences in their CSF metabolome compared to all other subjects, including subjects 
carrying other mutations on their SOD1 gene [49]. These two human ALS studies provided 
the impetus for performing preclinical metabonomic profiling of ALS. This in turn fuels the 
search for biomarkers relevant to preclinical disease progression, in-line with the 
recommendations made by the European ALS/MND group in 2006 [50] and subsequently an 
update in 2009 [51].  
 The aim of our study is to ascertain biological pathways inflicted in this relentless 
neurodegenerative disease in the SOD1G93A mouse model of ALS, with the potential of 
identifying metabolites that can be used as biomarkers for tracking efficacy in preclinical 
drug discovery, and ideally translatable into the clinics for prognosis and diagnosis of ALS. 
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2. Materials and Methods 
2.1  Animal Care 
 
Male B6SJL-Tg(SOD1*G93A)1Gur/J (mice hemizygous for the G93A mutant form of 
human SOD1 gene; SOD1G93A), B6SJL-Tg(SOD1)2Gur/J (mice carrying the normal allele of 
the human SOD1 gene; SOD1) and Non-carrier (NCAR) mice were purchased from The 
Jackson Laboratories (Bar Harbor, ME, USA). The mice were housed five per cage in the 
laboratory and maintained on a 12 h dark/light cycle in a room with controlled temperature 
(20 ± 1°C) and humidity (45 ± 5%). Food and water were available to the mice ad libitum. All 
experiments were performed at the Biological Resource Centre (BRC) rodent facility, 
Biopolis, Singapore. All studies were conducted in accordance with the GSK Policy on the 
Care, Welfare and Treatment of Laboratory Animals and were reviewed the Institutional 
Animal Care and Use Committee either at GSK or by the ethical review process at the 
institution where the work was performed. 
 
2.2  Biological Sampling for Metabolic Profiling 
 
The animals were observed twice a week. Observations and animal weights were 
recorded for the monitoring of disease progression until they were sacrificed at 112 days 
post-partum. The mice were sacrificed by rapid decapitation and whole blood was collected 




2.3  Sample Derivatisation 
 
Prior to metabolic profiling, 1 mL of monophasic extraction solvent of methanol was 
added to 100 µL of blood collected from each animal. The samples were vortex-mixed for 10 
min, and then centrifuged at 14,000 x g for 10 min. Supernatant from each sample was 
transferred into a 15-mL silanised (with silanization solution I, Sigma-Aldrich) glass tube. The 
supernatants were concentrated to complete dryness at a temperature of 50°C for 
approximately 30 min using the Turbovap nitrogen evaporator (Caliper Life Science, 
Hopkinton, MA). Subsequently, 100 μL of anhydrous toluene (stored with sodium sulfate) 
was added to each of the dried extracts. Following 1 min of vortex-mixing, the samples were 
evaporated to dryness using the evaporator to ensure the complete elimination of any 
traces of water which might interfere with the subsequent sample derivatisation. The dried 
metabolic extract was derivatized first with 50 μL of methoxyamine (20 mg/mL) for 2 h at 
60°C. Subsequently, 100 μL of N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) with 
1% trimethylchlorosilane (TMCS) (Sigma-Aldrich) was added to the mixture and heated for 1 
h at 60°C to form trimethylsilyl (TMS) derivatives. TMS derivatives were cooled, and 100 μL 
of each supernatant was transferred into GC vial and subjected to GC/TOFMS analysis, with 
the injection sequence being randomized. Quality Control (QC) samples were prepared by 
pooling 20 μL of derivative mix from 1 randomly selected sample from NCAR group and 
normal SOD1 group, and 2 randomly selected samples from the SOD1G93A group. QC 
samples were injected and analyzed at every 10 injections to monitor for GC/TOFMS 
analytical performance, and n-alkane standards (C10-40, all even; Sigma-Aldrich) injected at 





2.4  GC/TOFMS 
 
GC/TOFMS analysis was performed using 7890A Gas Chromatography (Agilent 
Technologies, Santa Clara, CA) coupled to PEGASUS 4D Time-of-Flight Mass Spectrometer 
(LECO Corporation, St. Joseph, MI). A DB-1 GC column (Agilent Technologies) with a length of 
23 m x 250 μm x 0.2 μm was used. Helium was used as the carrier gas at a flow rate of 1 
mL/min. An injection volume of 1 μL was used and the injector split ratio was set to 1:2. The 
front inlet and ion source temperatures were maintained at 250 and 200 °C, respectively. 
The primary column temperature was kept at 60°C for 0.2 min, then increased by 5 °C/min 
to 125°C and further increased by 15 °C/min to 270°C where it was held for 7 min for 
analysis. The MS mass range was m/z 50−650 with an acquisiƟon rate of 50 Hz. The detector 
voltage was set at 1650 V with electron energy of −70 eV. Solvent cutoﬀ Ɵme was 
determined to be 8.3 min. Chromatogram acquisition, data preprocessing (i.e. baseline 
correction, noise reduction, deconvolution, peak area calculation and alignment of retention 
time to generate a consistent data matrix) [52], and preliminary analyte identification by the 
National Institute of Standards and Technology (NIST) library were performed using the 
LECO ChromaTOF software version 4.21 prior to conducting multivariate data analysis for all 
the sample groups. A calibration table was created using peaks imported from one of the QC 
injections [52]. Artifact, noise and reagent peaks were deleted and additional peaks of 
interest were registered. “Retention time (RT) deviation” was set at 2 s for peak alignment 
[52].  All the samples in the metabonomic experiment were selected as standards and 
“calculate standards” option was used to initiate peak integration. Similarity threshold was 
set at 60% and peaks with similarity index of more than 60% were assigned putative 
metabolite identities based on the NIST mass spectral library [52]. Peak area integrations 
were checked manually and reintegration was performed in instances of misalignment. Once 
the iterative verification process is optimally performed for all the peaks, the metabolite 
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peak area values were exported as '.csv' format for data normalization in Microsoft Office 
Excel using total chromatographic area normalization [53]. 
 
2.5  Multivariate Data Analysis 
 
The resulting data was first processed by normalizing the peak area of each analyte 
against the total integral peak area of each sample using Microsoft Office Excel [53]. 
Coefficient of variance (CV%) was calculated for all putative metabolites using QC injections, 
and metabolites that gave CV% > 30 were discarded. All processed data were then mean-
centered and unit-variance scaled before it was subjected to principal component analysis 
(PCA) using SIMCA-P (Umetrics, Umeå, Sweden) to identify clustering trend, as well as detect 
and exclude outliers that fall out of the Hostelling’s Ellipse. Subsequent to the exclusion of 
sample outliers, the data were further subjected to partial least-squares-discriminant 
analysis (PLS-DA) for identification of discriminant metabolites that distinguish 2 sample 
classes. Two between-classes comparison experiments were performed: (1) between NCAR 
and SOD1 Tg and (2) between SOD1 Tg and SOD1G93A Tg. Variable importance in the 
projection (VIP) signifies the influence of the metabolites on the classification and its cutoff 
value was defined as 1.2. Welch’s T-test was then used for statistical comparison of 
discriminant metabolite levels between two test groups. Comparisons showing p-value of 
less than 0.05 were considered to be statistically significantly different for the discriminant 
metabolites. The chemical identities of the marker metabolites were confirmed by cross-
referencing with the Golm metabolite library[54] and the HMDB database [55] using the 




2.6  Pathway Analysis 
 
Putative identities of the shortlisted metabolites would be used as queries in a web-
based software Metaboanalyst 2.0 (http://www.metaboanalyst.ca ) [56]. Queries were 
entered as “Compound names” and “Mus musculus (mouse)” chosen as the species of 
relevance. For the pathway analysis algorithms, “Fisher’s Exact Test” and “Relative-
betweeness Centrality” chosen for “Over Representation Analysis” and “Pathway Topology 
Analysis” respectively. KEGG Pathway mapping (http://www.genome.jp/kegg/pathway.html) 
[57] was used to map the metabonomics data to the KEGG pathway maps, for biological 





3.1  Animal health 
 
Animals were initially scheduled to be euthanised and terminal samples to be collected 
on Day 120 postpartum, a general age that is defined as the advanced stage of disease 
progression for the BL6SJL strain mouse carrying the human SOD1 with the G93A mutation 
variant [16]. However, some of the 20 mice started showing impairment in the lower limbs 
when observed at Day 105. The decision was then made to collect the terminal samples 
earlier, and despite so, we were left with 18 mice when we harvested the samples on Day 
112. As recorded in Table 1, 6 out of 18 mice demonstrated some form of motor impairment 





Table 1. Weight and observation of mice prior to sample collection. ALS-related 
observations include a both hind limbs impaired, and b left hind limb impaired while right 
hind limb paralysed. Secondary observations include c dried wound spots on tail, d penile 
prolapse, e wound on dorsal back and penile injury, and f dried wound on tail. 
































  S0253 a 24.12 
S0254 27.30 
S0255 22.46 




  S0261 a 26.98 
 S0262 f 24.03 
S0263 25.08 
S0264 24.02 
  S0265 a 20.15 
  S0266 b 20.68 







3.2  Multivariate Data Analysis 
 
Close to 700 metabolite peaks were detected using GC/TOFMS, and after data 
preprocessing and calibration, the list narrowed to 479 metabolites. Peak area normalization 
was performed for each analyte against the total integral peak area of each sample. The final 
matrix table was imported into SIMCA-P v 13.0 for multivariate analysis. PCA showed that 4 
samples were found outside the Hotelling’s Eclipse in the scores plot and were considered 
outliers (Figure 1A). The remaining samples were subjected to PLS-DA. Clear clustering can 
be seen among each group with the 4 QC samples forming a tight cluster (Figure 1B). This 
reflected the low and acceptable analytical variations associated with sample preparation to 







B            
Figure 1. (A) PCA scores plot (R2X=0.715, Q2=0.48) showing 4 samples falling outside 
Hostelling’s Ellipse. (B) PLS-DA scores plot (with the 4 outliers excluded; R2X=0.35, 
R2Y=0.513, Q2=0.147), plotted with 3 latent variables. The QCs were tightly 
clustered, indicating the robustness of the sample processing and GC runs. Clear 
clustering of the 3 groups was observed in the PLS-DA scores plot, indicating that 




Table 2. PLS-DA classification to investigate metabolites which define the separation 
between the classes in the 2 comparison sets namely (1) NCAR vs SOD1 Tg, and (2) SOD1 
vs SOD1G93A Tg. 
Comparison   Class 1    Class 2   
1   NCAR    SOD1 Tg 
2   SOD1 Tg    SOD1G93A Tg 
 
A  
B    
Figure 2. PLS-DA were performed with the classifications specified in Table 2.       
Clear distinctions were shown between the 2 classes in each of the 2 comparisons;     
(A) between Non-Carrier and SOD1 Tg mice (R2X=0.377, R2Y=0.957, Q2=0.334),       




Samples from SOD1 Tg group and SOD1G93A Tg group were classified as class 1 and 2 
respectively with all other samples excluded in Comparison 2 (Table 2) and subjected to PLS-
DA. Using the criteria set as mentioned in Materials and Methods, briefly: VIP > 1.2, p < 0.05 
and CV% in QC injections < 30%, 70 metabolites were identified to be contributing 
significantly to the separation between SOD1 Tg mice and SOD1G93A Tg mice in the PLS-DA. 
11 of which were later excluded as they too were found to be significantly different (p<0.05) 
in Comparison 1 (between wildtype Non-Carrier and healthy SOD1 Tg mice). These 11 
metabolites were differentially expressed in the 2 healthy genotypes, therefore including 
them into our subsequent analysis for differences in the metabolome between SOD1 Tg 
mice and SOD1G93A Tg mice could confound the analysis. 2 more metabolites were 
removed as the matched identities indicated that these 2 peaks were artifacts derived from 
the derivatizing agents. This resulted in 57 metabolites that contributed significantly to the 






Table 3. List of blood marker metabolites identified from PLS-DA of SOD1 Tg and 
SOD1G93A Tg mice.  














Met_402 MyoInositol-2-phosphate  ** 
>2.0 
1.833 Ï 9.13 GMD
Met_386 3-phosphoglycerate ** 1.703 Ð 6.06 NIST
Met_438 Isomaltose *** 1.508 Ð 4.32 GMD
Met_415 Glyceric acid-1,3-diphosphate *** 2.637 Ï 6.64 GMD
Met_312 9-Tetradecenoic acid *** 2.385 Ð 4.67 NIST
Met_352 11-Eicosenoic acid *** 1.374 Ð 4.23 NIST
Met_236 Homovanillic acid *** 1.412 Ï 7.92 GMD
Met_194 5-(aminomethyl)-isoxazol-3-ol 
1.5 – 2.0 
1.647 Ð 4.89 NIST
Met_408 Inosine 1.417 Ð 3.19 NIST
Met_406 4-Ketoglucose 1.419 Ð 2.61 GMD
Met_216 3-oxalo-Malic acid 1.624 Ð 2.21 GMD
Met_221 Lyxonic acid-1,4-lactone 1.442 Ð 9.39 GMD
Met_188 5-Methyl-acetophenone 1.110 Ï 0.91 NIST
Met_403 Phthalic acid, cyclohexyl 2-pentyl ester 1.228 Ï 5.61 NIST 
Met_317 Hexadecanoic acid ** 1.295 Ð 7.15 GMD
Met_152 Methanesulfinic acid, trimethylsilyl ester ** 2.885 Ï 11.17 NIST 
Met_171 D-mannopentadecane-1,2,3,4,5-pentaol ** 1.802 Ð 16.49 NIST 
Met_233 4-[Acetyloxy-(2-pyridyl)methyl]-1,2-dihydro-2-oxoquinoline 1.125 Ï 1.40 NIST 
Met_436 Uridine 5'-monophosphate * 1.507 Ï 5.83 GMD
Met_465 Cholesterol-epoxide ** 1.788 Ï 11.98 GMD
Met_458 4-(2,2-dimethyl-6-methylene-cyclohexyl)-butan-1-ol ** 1.846 Ï 2.80 NIST 
Met_385 Glyceric acid-2,3-diphosphate 1.372 Ð 4.33 NIST
Met_242 Oxytetradecanoic acid 3.729 Ï 11.54 NIST
Met_039 
9,12-Octadecadienoic acid (Z,Z)-, 2-
(acetyloxy)-1-
[(acetyloxy)methyl]ethyl ester 
1.114 Ï 3.94 NIST 





1.101 Ï 1.55 NIST 
Met_019 3-hydroxy-Butanoic acid 1.419 Ð 4.34 GMD
Met_212 2-Hexenal, 5-(1-ethoxyethoxy)-, [R*,S*-(E)]-(.+-.)- ** 1.139 Ï 2.84 NIST 
Met_180 1H-Indole-2,3-dione 1.526 Ï 9.10 NIST
Met_225 Glycerol-2-phosphate ** 1.192 Ð 3.03 GMD
Met_223 Orotic acid 1.593 Ï 23.71 GMD
Met_112 1,6-dimethoxy-2,4-Hexadiene 1.639 Ï 9.65 NIST





1.113 Ï 3.13 NIST 
Met_277 Thiocyanic acid, 2,4,6-trinitrophenyl ester 1.407 Ï 2.96 NIST 
Met_191 a-methyl-3-phenoxy-Benzeneacetic acid 1.708 Ð 6.91 NIST 
Met_252 Unknown 1.119 Ï 1.32 - 
Met_016 Unknown 1.425 Ï 6.52 - 
Met_024 Unknown  ** 1.462 Ï 2.36 - 
Met_200 Methanesulfinic acid 1.120 Ï 3.46 NIST
Met_251 2-amino-3-methoxy-Benzoic acid 1.117 Ï 0.83 GMD
Met_078 Glycerol  
 
 




1.338 Ð 2.92 GMD
Met_372 Xylitol 1.246 Ð 5.87 NIST
Met_432 2-methoxy-2-methyl-Propane 1.138 Ï 3.24 NIST
Met_267 Glucopyranose 1.583 Ï 20.88 GMD
Met_389 Acetic acid 1.494 Ï 3.94 NIST
Met_407 Docosahexaenoic acid, 4,7,10,13,16,19-(Z,Z,Z,Z,Z,Z) 1.186 Ð 17.75 GMD 
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1.2 – 1.5 
1.267 Ð 13.92 NIST
Met_395 Uridine 1.464 Ð 10.83 GMD
Met_453 Cholest-5-ene 1.243 Ï 3.72 GMD/NIST
Met_199 Quinoxaline-6-carboxamide 1.752 Ð 4.00 NIST





1.865 Ï 9.15 NIST 
Met_098 Homoserine 1.465 Ð 7.16 GMD
Met_464 Prost-13-en-1-oic scid 1.771 Ï 4.83 NIST
Met_421 Methylmalonate 1.248 Ï 14.09 NIST
Met_255 Ribonic acid 1.219 Ï 3.21 NIST
All listed metabolites are identified with VIP>1.2 and found to be statistically significant with p-value of less 
than 0.05, calculated with Welch’s T-test. The CV% of these metabolites in the pooled QC samples are less 




3.3  Pathway Analysis 
 
Among the 57 marker metabolites, 54 metabolites with putative identities were further 
subjected to web-based pathway analysis  (Metaboanalyst) [56]. Before we could perform 
any functional pathway analysis, a match between the compound names provided by the 
library sources (NIST and GMD) and the ones in MetaboAnalyst’s knowledgebase had to be 
established (Table 4). In some cases, there might be redundancies and conflicts due to 
different naming schema. The compounds with name conflicts were highlighted for 
subsequent manual inspection.  Based on the 54 compounds names presented to the 





Table 4. List of metabolites input into MetaboAnalyst for pathway analysis and their 
corresponding matches based on MetaboAnalyst’s knowledgebase. 
Query Match 
MyoInositol-2-phosphate Myo-inositol 1-phosphate 
3-phosphoglycerate 3-Phosphoglyceric acid 
Isomaltose Isomaltose 
Glyceric acid-1,3-diphosphate Glyceric acid 1,3-biphosphate 
9-Tetradecenoic acid Myristoleic acid 
11-Eicosenoic acid 11-Eicosenoic acid 




3-oxalo-Malic acid 3-Oxalomalate 
Lyxonic acid-1,4-lactone Threonolactone 
5-Methyl-acetophenone 2-Methylacetophenone 
Phthalic acid, cyclohexyl 2-pentyl ester - 
Hexadecanoic acid Palmitic acid 




Uridine 5'-monophosphate Uridine 5'-monophosphate 
Cholesterol-5alpha,6beta-epoxide - 
4-(2,2-dimethyl-6-methylene-cyclohexyl)-butan-1-ol gamma-Ionone 
Glyceric acid-2,3-diphosphate Glyceric acid 1,3-biphosphate 
oxytetradecanoic acid 2-Hydroxymyristic acid 
9,12-Octadecadienoic acid (Z,Z)-, 2-(acetyloxy)-1-
[(acetyloxy)methyl]ethyl ester Methyl linoleate 
Oxalic acid Oxalic acid 
5-Amino-2-isopropyl-1-phenyl-2,3(1H)-dihydro-pyrrole-
3,3,4-tricarbonitrile - 
3-hydroxy-Butanoic acid 3-Hydroxybutyric acid 
2-Hexenal, 5-(1-ethoxyethoxy)-, [R*,S*-(E)]-(.+-.) - 
1H-Indole-2,3-dione Indole-5,6-quinone 
Glycerol-2-phosphate Beta-Glycerophosphoric acid 





Thiocyanic acid, 2,4,6-trinitrophenyl ester - 
a-methyl-3-phenoxy Benzeneacetic acid - 
Methanesulfinic acid S-Methyl methanesulfinothioate 





Acetic acid Acetic acid 
Docosahexaenoic acid, 4,7,10,13,16,19-(Z,Z,Z,Z,Z,Z) (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid 










Prost-13-en-1-oic scid Prostaglandin E1 
Methylmalonate Methylmalonic acid 





Identified pathways using Metaboanalyst are presented in Table 5. They included 
glycolysis, pentose and sucrose metabolism, fatty acids elongation and biosynthesis, 
among others. Kyoto Encyclopedia of Genes and Genomes, KEGG[57], is a database 
resource for understanding high-level functions and utilities of the biological system, 
such as the cell, the organism and the ecosystem, from molecular-level information, 
especially large-scale molecular datasets generated by genome sequencing and other 
high-throughput experimental technologies. KEGG PATHWAY mapping is the process to 
map molecular datasets, especially large-scale datasets in genomics, transcriptomics, 
proteomics, and metabolomics, to the KEGG pathway maps for biological interpretaion 
of higher-level systemic functions. Based on KEGG analysis, the pathways were further 
classified into 4 major functions namely, carbohydrate metabolism, lipid metabolism, 





Table 5. Biological pathways and systemic functions implicated in SOD1 mutation as 
uncovered by global blood metabonomic profiling. 
Biological Pathway Metabolite IDs Systemic Function 
Glycolysis or Gluconeogenesis D-glucose, Glyceric acid 1,3-biphosphate, Acetic acid, 3-phosphoglycerate 
Carbohydrate Metabolism 
Pentose phosphate pathway D-glucose 
Pentose and glucuronate 
interconversions D-xylitol 
Galactose metabolism Glycerol 
Starch and sucrose metabolism Isomaltose 
Pyruvate metabolism Acetic acid 
Butanoate metabolism 3-Hydroxybutyric acid 
Inositol phosphate metabolism Myo-inositol 1-phosphate 
Fatty acid metabolism Palmitic acid 
Lipid Metabolism 
Fatty acid biosynthesis Myristic acis, Palmitic acid 
Fatty acid elongation in mitochondria Palmitic acid 
Synthesis and degradation of ketone 
bodies 3-Hydroxybutyric acid 
Biosynthesis of unsaturated fatty 
acids Palmitic acid, Docosahexaenoic acid 
Glycerolipid metabolism Glycerol 
Purine metabolism Inosine 
Nucleotide Metabolism 
Pyrimidine metabolism Uridine 5'-monophosphate, Orotic acid, Uridine 
Valine, leucine and isoleucine 
metabolism Methylmalonic acid Amino acid metabolism 






4.1  Changes in carbohydrate metabolism 
 
Abnormalities in carbohydrate metabolism in ALS patients have long been suggested. 
As early as in the 70’s, ALS patients had been found to have a high incidence of diabetes, 
with a large proportion having abnormal glucose tolerance [59]. The latter has been recently 
verified to be the case even in non-diabetic ALS patients and suspected to be in association 
with increased levels of free fatty acids [60]. In the same year when the discovery of the 
G93A mutant of the human SOD1 gene in association to the disease had been published 
[11], investigation showed enhanced metabolism of glucose to fructose in muscle isolated 
from ALS patients [61]. There were also evidence that showed increased ketohexokinase 
activities and aldolase, which suggested that further metabolism of fructose may occur via a 
fructolytic pathway. In our work, high blood glucose has also been measured. Glycolysis 
intermediate 1,3-biphosphate glycerate has been detected at a higher level compared to the 
healthy SOD1 Tg control mouse, with a decrease in 3-phosphoglycerate (Table 3). These 
point to a reduction in ATP synthesis via the glycolytic process. Acetic acid, involved in the 
initiation of the Tricarboxylic Acid (TCA) cycle after its activation, has also been found to be 
in excess in the diseased animal (Table 3). The degeneration of motor units, composed of 
different kinds of motor neurons and muscles fibers, represents the first detectable event in 
ALS [62, 63]. Fast fatigable motor units are composed of large alpha-motor neurons and 
glycolytic muscle fibers that preferentially burn glucose to exert heavy force for a short 
period. Conversely, slow motor units correspond to small alpha-motor neurons and 
oxidative muscle fibers, which store and use fatty acids preferentially to produce less intense 
but constant strength. Large alpha-motor neurons are the first to degenerate in ALS models 
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[63, 64], and glycolytic motor units are preferentially affected in both ALS patients and 
mouse models [65-67]. The selective vulnerability of large alpha-motor neurons is 
potentially due to their higher energetic needs that could either be not fulfilled or a source 
of oxidative stress. The animals were in the advanced stage of the disease and hind limb 
impairment had set in (Table 1); in some there were almost complete lower limb paralysis. It 
is therefore likely that the glycolytic muscles in these animals had been so affected that the 
reduction in the glycolytic process is evident in the systemic blood circulation of the animals. 
In fact, even in the early stages of disease progression, the glycolytic muscles of SOD1G93A 
Tg mice switched toward an oxidative phenotype, presumably due to the loss of their 




4.2  Hypermetabolism 
 
Hypermetabolism has been consistently reported in ALS patients [69-72]. Patients lose 
some weight due to the inevitable reduction in skeletal muscle mass resulting from 
denervation and decreased physical activity. In most cases weight loss also has a nutritional 
component attributable to malnutrition, the principal cause of which is decreased dietary 
intake. Swallowing disorders and dysphagia affect most ALS patients. Anorexia, digestive 
disorders and upper extremity motor difficulties also contribute to low dietary intake. 
Another cause of malnutrition is an increase in energy requirements sufficient to exceed 
dietary intake. Reports that resting energy expenditure (REE) may be increased in this 
context [71, 73, 74] appear paradoxical because free fat mass (FFM), the main determinant 
of REE, decreases in ALS due to reasons discussed above. Kasarskis et al. [74] suggested that 
hypermetabolism in ALS probably reflected added energy demand due to increased 
respiratory work. They found that REE increased as death approached whereas forced vital 
capacity (FVC) declined, as did BMI and FFM. However, REE was not studied in relation to 
FFM, and the evolution of REE and FVC was evaluated by looking at variations between 
patients at different stages of disease rather than by following individual patients as they 
progressed. Energetic alterations are similarly found in the SOD1 transgenic mouse model of 
ALS. Apart from producing less ATP due to the switching off of the glycolytic process 
(glycolysis itself produces 2 ATP in each glucose molecule), the dysfunctional electron 
transport chain have also resulted in ATP synthesis taking place inefficiently [75]. These mice 
are leaner than controls, hypermetabolic, hypolipidemic and present increased fatty acid 
uptake in muscles [76, 77]. In case of higher energy needs, neurons can use ketone bodies as 
an energetic substrate when glycolysis can no longer sustain the ATP demand of the system 
[78]. In this situation, astrocytes will use lipid to provide ketone bodies to neurons, and 
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potentially motor neurons in ALS [79]. The blood concentration of 3-hydroxybutyric acid, the 
major of the 3 ketone bodies (with acetoacetate and acetone), was found to be lower in the 
mutant SOD1 model than that of matched controls in our current study (Table 3). At the 
same time, medium length fatty acids like myristic acid, palmitic acid and docosahexaenoic 
acid (DHA) were also found to be at lower abundance when compared against their levels in 
matched controls (Table 3). Therefore a similar shift from utilising glucose to using ketone 
bodies and fatty acids to fuel the TCA cycle was observed in the SOD1G93A mice. 
Encouragingly, our preclinical observations of perturbed carbohydrate and lipid metabolism 
corroborated with the findings of a recent clinical study that profiled blood markers 
associated with ALS patients when compared to disease mimic patients and healthy 





4.3  Nucleoside / Nucleotide Metabolism 
 
Uridine is a pyrimidine nucleoside that is required for phospholipid, glycogen, and RNA 
synthesis [81]. The increase of orotic acid and uridine 5’-monophosphate with the decrease 
in level of uridine may indicate the fall in de novo synthesis of uridine (Figure 3). The fact 
that uridine is a key metabolite is illustrated by the rare, inherited form of the disease orotic 
aciduria in humans due to deficiencies of the enzyme uridine monophosphate synthetase 
(UMPS). This deficiency leads to mental retardation and the failure to thrive. Inherited orotic 
aciduria in humans is treated by uridine supplement thus bypasses the metabolic block due 
to UMPS dysfunction. Much of the cytidine 5’-triphosphate (CTP) utilized in the Kennedy 
cycle for synaptogenesis in the human brain is derived from uridine [82, 83]. The CNS uptake 
of uridine, the principle circulating pyrimidine, occurs from the circulation through the 
blood- brain barrier primarily by the sodium-dependent CNT2 nucleoside transporter [84] 
and enters into cells via an ATP driven uridine-UTP cycle [85] where interconversion to 
largely non-circulating essential compounds occurs. In the SOD1G93A mouse, uridine 
administration increased survival by 17.4%, ameliorated body weight loss, enhanced motor 
performance, reduced gross lumbar and ventral horn atrophy, attenuated lumbar ventral 
horn neuronal cell death, and decreased reactive astrogliosis [86]. Uridine synthesis is 
located on the inner mitochodrial membrane and coupled functionally with ubiquinone. The 
formation of uridine requires functioning mitochondria, and uridine is necessary to support 
the growth of cells that lack mitochondria [87].  
Purines and pyrimidines are potent signaling molecules which target a broad range of 
tissues and cell types [88]. The extracellular release of nucleosides and nucleoside tri-
phosphates (NTPs), especially adenosine and ATP respectively, is a common feature of 
various cells under different conditions, such as muscle, lymphocytes, neurons and glial cells 
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which have prominent roles in ALS [89]. Considering that extracellular purines and 
pyrimidines are crucial neuron-to-microglia alarm signals in the CNS, and that ALS is the 
result of a multipart anomalous cellular interplay, it seems highly possible that purinergic 
dynamics might indeed also have a certain role in the onset and progression of ALS. Target 
receptors include 7 ionotropic P2X channels (P2X1–7) [90], 8 G-protein-coupled P2Y 
receptors (P2Y1, 2, 4, 6, 11–14) [91], 4 G-protein-coupled P1 receptors (A1, A2A, A2B, A3) 
[92]. A2A receptor antagonists such as preladenant, are in trial for the treatment of early 
Parkinson's disease (www.clinicaltrial.gov), and istradefylline (KW-6002) for Parkinson's 
disease symptoms and dyskinesia that develops after a long-term treatment with levodopa 
[93]. The P2X7 receptor has been targeted by antagonists: Pfizer's CE-224535, AstraZeneca's 
AZD-9056 and Evotec's EVT-401, to reduce inflammation in peripheral pathologies [94], and 
the potential of CNS indications is in discussion. The decrease in systemic inosine (Table 3), 
possibly adenosine and ATP as well, could result in a downregulation in inflammatory 
responses. Whether or not it is an innate defense mechanism awaits investigation. More 
likely, the low inosine level is a consequence of a lower ATP production (Figure 4) due to the 
shut down of glycolysis in the cytosol on top of the inefficient oxidative phosphorylation 





Figure 3. Pyrimidine de novo synthesis pathway [95]. 1, carbamylphosphate 
synthetase; 2, aspartate transcarbamylase; 3, dihydroorotase; 4, dihydroorotate 
dehydrogenase; 5, orotate phosphoribosyltransferase; 6, orotidine 5′-
monophosphate decarboxylase; 5 + 6, UMP synthase; 7, orotidine 5′-
monophosphate phosphohydrolase; 8, pyrimidine 5′-nucleotidase; 9, uridine kinase;  
Graphic, uridine phosphorylase. 
 
Figure 4.  Biochemical pathways involved in skeletal muscle inosine monophosphate 
(IMP) metabolism [96]. 1, ATPase; 2, adenylate kinase; 3, AMP deaminase; 4, 
cytoplasmic 5’-nucleotidase; 5, purine nucleoside phosphorylase; 6, xanthine 
oxidase; 7, adenylosuccinate synthetase; 8, adenylosuccinate lyase; 9, 
hypoxanthine/guanine 5-phosphoribosyl 1-pyrophosphate (PRPP) transferase. 
sAMP, succinyl AMP; PNC, purine nucleotide cycle. 
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4.4  Dopaminergic Systems 
 
It has been suggested that there is impairment of the central dopaminergic systems in 
ALS patients, thus suggesting that there is degeneration of neuroanatomical structures other 
than motor neurons [97]. Indeed the depletions of dopamine and homovanillic acid (HVA) 
were significantly greater in the striatal tissues of SODG93A Tg mice compared to their 
littermate control mice [98]. HVA, a breakdown product of dopamine as well as 
noradrenaline, has been found to be elevated in plasma under metabolic stress [99, 100]. 
Plasma HVA, although largely derived from the periphery, is thought to reflect, at least 
partly, the central dopamine response to stress [100, 101]. Indeed in our metabolic profile, 
HVA was significantly elevated in the blood of mice carrying the mutant human SOD1 (Table 
3), indicative of dopaminergic breakdown. There were only a couple of studies published in 
the 1990s that investigated the association between HVA and ALS [97, 102], and after that 
more often than not, HVA changes have been associated with Parkinson Disease only. The 







The pathophysiological mechanisms underlying ALS are multifactorial, with a complex 
interaction between genetic factors and molecular pathways that remain to be better 
understood. Proposed mechanisms that are involved in the pathology of ALS include 
glutamate excitotoxicity, protein misfolding, oxidative stress, mitochondrial dysfunction, 
defective axonal transport, neuroinflammation, altered energy metabolism, and recently 
RNA misprocessing [12, 103]. The fact that mitochondria are compromised in ALS is 
apparent from multiple studies performed using cellular or animal models of disease and in 
patients. Early studies on post-mortem tissues of ALS patients identified structural and 
morphological abnormalities in mitochondria of skeletal muscle, liver, spinal cord neurons 
and motor cortex at the electron microscopic level [104, 105]. Despite recent advances, the 
human mutant SOD1 remains the most studied ALS-associated gene and the SOD1G93A Tg 
mouse being the choice of disease model for pharmacological screening.  Various 
mechanisms had been proposed by which mutant SOD1 exerts its toxicity on mitochondrial 
functions. Evidence indicates that mutant SOD1 directly interacts with Bcl-2, leading to 
exposure of the toxic BH3 domain, which in turn causes mitochondrial damage [106]. 
Protein misfolding and aggregation is common hallmark of numerous neurodegenerative 
diseases. Many FALS-link SOD1 mutants, including SOD1G93A, have an increased propensity 
to misfold due to specific alterations in their amino acid sequence, which in turn affects the 
dynamics and stability of the protein’s tertiary structure [107]. Interestingly certain aberrant 
post-translational modifications can also cause wild type SOD1 to misfold as well. More 
recently, uptake of both misfolded mutant-SOD1 as well as aggregated mutant-SOD1 was 
shown to induce misfolding, and subsequently aggregation of the native wild type SOD1 
protein [108]. Therefore, it has also been suggested that mutant SOD1 may alter wild type 
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SOD1’s dismutase activity, presumably via this “prion-like” manner [108, 109], thus 
presenting a “gain in toxic function”. This caused superoxide and ROS to build up in the 
respiring mitochondria of large alpha-motor neurons, which was mentioned earlier to be the 
more susceptible subtype. In synergy with the persistent activation of Nox2 and abnormally 
high levels of ROS from the alternation of the SOD1/Rac1 interaction [110], the fast motor 
neurons gradually die off due to accumulated oxidative stress. It has also been suggested 
that the defective axonal transport of mitochondria in SOD1G93A mouse is responsible for 
the “die-back” phenomena in which motor neurons retracts back from the neuromuscular 
junctions, breaking the communication with muscle fibers. As the glycolytic muscle fibers 
lose their connections with motor neuron, the slower small alpha-motor neurons may re-
innervate these muscle fibers [68], resulting in the switching of ATP generation of the motor 
unit from glycolytic, to using oxidative phosphorylation. Since glycolysis has been shut down 
and the body goes into a state of hypermetabolism, alternative sources of acetyl-CoA (via β-
oxidation of fatty acids, and ketone bodies) are needed to feed the TCA cycle, which in turns 
provides NADH and succinate to drive the electron transport chain to generate ATP via 
oxidative phosphorylation.  
Our untargeted metabonomic approach confirmed that the downstream events of 
mitochondrial dysfunction associated with ALS can be profiled preclinically. These include 
changes in carbohydrate metabolism to signs of hypermetabolism. Such perturbation in 
energy metabolism may occur regardless of the initial cause of the disease, be it genetic via 
mutations, or sporadic. There is however a caveat in our study: the identities of the marker 
metabolites are at the moment putative. One of the important but challenging steps in 
metabonomics is the determination of the identities of marker metabolites [111]. Utmost 
effort has been put in to ensure that the identification of metabolites does not only rely on 
the level of electron impact (EI) spectral match, but also include RIs in order to optimize the 
quality and reliability of library hits [112]. RIs are the relative retention times (RRT) 
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normalized to adjacently eluting n-alkanes [113]. Although RT can vary with the individual 
chromatographic system, the RIs of metabolites are comparable between analytical 
laboratories under varying conditions [114]. It is however encouraging that in a recent 
publication, Lawton et al. employed a similar GC/MS human plasma profiling approach to 
profile ALS and detected a similar subset of marker metabolites [80]. Their findings 
therefore cross-validate. They identified a panel of 32 metabolites as biomarkers that 
differentiated ALS patients from disease mimics such as autoimmune motor neuropathy, 
spinal muscular atrophy, Kennedy’s disease, cervical myelopathy, multiple sclerosis and 
hereditary spastic paraparesis [80]. Common pathways that were identified in the clinical 
study and our current preclinical study were energy, lipids, amino acids and nucleotides 
metabolisms. The specific metabolites that were identified in both studies were mainly the 
fatty acids (myristic acid, palmitic acid, cholesterol and DHA) and ketone bodies (3-
hydroxybutyrate). However, the changes in the identified metabolites levels are not aligned: 
the fatty acids and ketone bodies in our study were found to be lower in the SOD1G93A Tg 
mice, however they were elevated in the plasma of ALS patients when compared against 
both patients of disease mimics and healthy subjects [80]. In the clinical study, the ALS 
patients were newly diagnosed; and furthermore, based on the reported ALS Functional 
Rating Scale (ALSFRS-R) scores [115], most of the patients were at an early stage in the 
disease progression when ALS is most difficult to diagnose; 75% of the patient ALSFRS-R 
scores were over 35 and only 4% of ALS patients enrolled in the study recorded scores of 24 
or less. Usually, an ALSFRS-R score cut-off of 24 is used to distinguish high from low disease 
severity. In short, the plasma samples were derived from patients who are probably in the 
early stage of disease, or exhibited mild disease symptoms. In contrast, as this is a very first 
attempt to discern potential metabolic changes in a disease phenotype, we chose to use 
mice that were in the advanced stage of disease state for this current study (Table 1). This 
may explain the discrepancy in the relative expression of the respective metabolites. The 
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perturbation of energy metabolism however is in agreement in both studies; the decrease of 
inosine in our study (Table 3) and the decline in the levels of metabolites of xanthine 
metabolism in the clinical study [80] point to a reduction in ATP production and energy 
metabolism (Figure 4). The biomarker urate, an antioxidant, and the final product of 
xanthine metabolism, was lower in the plasma of ALS patients and was positively correlated 
with their ALSFRS-R scores, consistent with earlier reports [116, 117]. 
There has always been a concern about using the SOD1G93A Tg mouse model of ALS in 
the preclinical development of ALS intervention: whether results seen in the mouse model 
can be translated to human patients [20, 21]. Conventionally, pharmacodynamic assays have 
been performed with the disease models against healthy wild type controls. In our present 
study, we tried to eliminate any interference that can potentially come from the 
introduction of an exogenous gene into the mouse genome, by first excluding metabolite 
perturbation that is found between the 2 groups of healthy controls: the wild type strain-
matched non-carrier and mouse carrying the normal human SOD1 gene. Given that there is 
a high degree of overlap in the pathways identified in both clinical and preclinical studies, 
and that in the clinical study, the patients showed different genetic backgrounds (i.e. patient 
population consists of both SALS, and FALS, of which, are not limited to the ones which were 
caused by mutations of the SOD1 gene), the common marker metabolites and perturbed 
pathways could be utilised preclinically to monitor disease progression and pharmacological 
effects with therapeutic interventions. With the findings by Lawton et al., this may also be 
an opportunity for a translatable pharmacodynamic model to be developed. The model may 
be utilized from the preclinical phase of drug discovery, to the clinical monitoring of effects 
of therapies on ALS patients.  As such, future studies designed to represent the full range of 
ALS disease severity, preferably longitudinally, with proper validation of metabolites using 
analytical standards, could further explore the correlation of these biochemical pathways 
with disease progression. Additionally, an opportunity for subject stratification was 
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presented; of the 18 animals from the SOD1G93A Tg group, 6 showed impairments and/or 
paralysis of the lower limbs. It is possible for us to group these 6 mice as a separate class in 
attempt to further identify the metabolites that potentially differentiated these mice with 
apparent earlier onset of disease. Unfortunately, due to time factor, we did not manage to 
do it, but definitely something worth looking into even outside the content of this thesis. 
And if successful, it would no doubt be very exciting if this stratification of subjects by 
metabolite markers is translatable to the clinic as well. Lastly, our untargeted approach in 
metabolomics has rekindled the possibility of the central dopaminergic system being 
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